Recombination Therapeutics is a preclinical DNA Damage Response (DDR) biotechnology company focused on developing best-in-class personalized cancer therapeutics. Recombination Therapeutics was established with the goal of developing next-generation precision medicines for cancers with genetic defects in the DNA repair pathway called homologous recombination. Recombination’s lead program is targeting DNA polymerase Theta (Polq) which is essential for the proliferation of recombination deficient cancer cells, but is dispensable for normal cells.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.recombinationtx.com
Recombination Therapeutics Questions
Recombination Therapeutics's website is http://www.recombinationtx.com
Recombination Therapeutics's LinkedIn profile is https://www.linkedin.com/company/recombinationtx
Recombination Therapeutics has
3 employees.
View email and phone details for 3
employees at Recombination Therapeutics.
Recombination Therapeutics's industry is
Biotechnology Research
Recombination Therapeutics's top competitors are
Exin Biopharma Inc.,
Red Ace Bio,
Vertical Longevity Pharmaceuticals,
Spacerx,
Combined Ingenuity,
Higher Medicine,
Chariot Biosciences,
Reengage Therapeutics,
Quneup®,
Eldari Bio.
Recombination Therapeutics's categories are Biotechnology Research
Recombination Therapeutics's founding year is 2018
